Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Pyoderma Gangrenosum
NCT02326740Phase 3
Key facts
- Status
- Terminated
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Countries
- 3
- Sponsor
- XOMA
- Modality
- Monoclonal Antibodies
- Drugs
- gevokizumab
- Conditions
- pyoderma gangrenosum (PG)
01
Overview
Phase 3, randomised, double-blind trial of gevokizumab in pyoderma gangrenosum (PG) (3 arms), sponsored by XOMA. Primary endpoint: Proportion of subjects with complete closure of the PG target ulcer at Day 126. Started Dec 2014; status: terminated.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Gevokizumab
Gevokizumab subcutaneous injection (Part 1)
Placebo
Placebo subcutaneous injection (Part 1)
Gevokizumab Open-Label
Gevokizumab open-label treatment (Part 2)
03
Who it enrols
Patients with a clinical diagnosis of classic pyoderma gangrenosum and an active ulcer. Excludes patients with acutely infected PG, history of recurrent systemic infections, or allergy to monoclonal antibodies.
04
Endpoints
Primary
Proportion of subjects with complete closure of the PG target ulcer
Secondary
Proportion of subjects with reduction in target ulcer area
Beyond the preview
Go deeper on NCT02326740.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326740.